» Authors » Stephan Polterauer

Stephan Polterauer

Explore the profile of Stephan Polterauer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 126
Citations 1491
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Kurtz J, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, et al.
J Clin Oncol . 2023 Aug; 41(30):4768-4778. PMID: 37643382
Purpose: Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic with bevacizumab and...
12.
Eckel F, Carlin G, Mayer S, Polterauer S, Chalubinski K
J Clin Med . 2023 Aug; 12(16). PMID: 37629439
Krukenberg tumors are metastatic tumors of the ovaries, associated with poor outcomes. Most commonly, these tumors are of gastric origin. The diagnosis of Krukenberg tumors in pregnant patients is extremely...
13.
Zapardiel I, Gracia Segovia M, Macuks R, Mancari R, Achimas-Cadariu P, Corrado G, et al.
Int J Gynecol Cancer . 2023 May; 33(6):897-904. PMID: 37192761
Objective: Uterine sarcomas are a rare and heterogeneous group of malignancies that include different histological sub-types. The aim of this study was to identify and evaluate the impact of the...
14.
Tempfer C, Horn L, Ackermann S, Dittrich R, Einenkel J, Gunthert A, et al.
Geburtshilfe Frauenheilkd . 2023 Apr; 83(3):267-288. PMID: 37020431
The aim was to develop and update a guideline which would improve the quality of care offered to women with gestational and non-gestational trophoblastic disease, a group of diseases characterized...
15.
Gracia M, Yildirim Y, Macuks R, Mancari R, Achimas-Cadariu P, Polterauer S, et al.
Cancers (Basel) . 2023 Mar; 15(5). PMID: 36900255
Background: The aim of this study was to assess the impact of prognostic factors on the survival of patients diagnosed with uterine carcinosarcoma. Methods: A sub-analysis of the SARCUT study,...
16.
Sabatier R, Rousseau F, Joly F, Cropet C, Montegut C, Frindte J, et al.
Eur J Cancer . 2023 Jan; 181:42-52. PMID: 36634389
Background: The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance...
17.
Onoprienko A, Hofstetter G, Dorittke T, Bekos C, Grimm C, Polterauer M, et al.
J Pers Med . 2022 Dec; 12(11). PMID: 36579608
The present study aims to evaluate the pretherapeutic Fibrinogen-Albumin-Ratio Index (FARI), as currently reliable biomarkers to predict therapy response and prognosis of patients with advanced vulvar cancer are missing. Data...
18.
Grech C, Pils D, Aust S, Grimm C, Polterauer S, Reinthaller A, et al.
J Pers Med . 2022 Sep; 12(9). PMID: 36143252
PARP inhibitors (PARPi) have increased treatment options in ovarian cancer, particularly in patients with BRCA1/2 mutations, although there are still marked differences in the duration of patients' response to this...
19.
Reiser E, Pils D, Grimm C, Hoffmann I, Polterauer S, Kranawetter M, et al.
Cancers (Basel) . 2022 Jul; 14(13). PMID: 35804981
Discrimination between benign and malignant adnexal masses is essential for optimal treatment planning, but still remains challenging in a routine clinical setting. In this retrospective study, we aimed to compare...
20.
Marth C, Abreu M, Andersen K, Aro K, de Lurdes Batarda M, Boll D, et al.
Cancer . 2022 Jun; 128(16):3080-3089. PMID: 35714310
Background: This study aimed to describe the treatment strategies and outcomes for women with newly diagnosed advanced high-grade serous or endometrioid ovarian cancer (OC). Methods: This observational study collected real-world...